3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
45
Neoplasm Metastasis
5
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms, Castration-Resistant
2
Ovarian Neoplasms
2
Metastatic Castration-Resistant Prostate Cancer
2
Melanoma
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Bulbo-Spinal Atrophy, X-Linked
2
Bites and Stings
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Salivary Gland Neoplasms
1
Prostate Cancer Metastatic Disease
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Hormone-Sensitive Prostate Cance
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Interventions
darolutamide
2
olaparib
1
gedatolisib
1
gallium 68 PSMA-11
1
Surveys and Questionnaires
1
Radiotherapy
1
Prostate-Specific Antigen
1
Pluvicto
1
Nivolumab
1
Lutetium-177
1
Lutetium
1
Cryotherapy
1
Brachytherapy
1
Androgen Antagonists
1
Abiraterone Acetate
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
(225)Ac-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Prostatic Diseases
×
abiraterone
×
1 year
×
Clear all
No trials found.